Overall world revenue for Bleeding Disorder Treatment will surpass $6bn in 2017

LONDON, Nov. 8, 2017 /PRNewswire/ -- Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and...